This indicates that relatively lower CEACAM6 expression levels before chemotherapy are associated with achieving pCR following NAC, supporting its potential as both a predictive and therapeutic biomarker for the efficacy of neoadjuvant treatment in breast cancer. This evidence concerns the gene CEACAM6 and breast carcinoma.